Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication
Fig 2
Effect of PASylated IFN-1ant on ISG expression levels.
Expression of ISGs assessed by RNA sequencing in ART-treated and ART-untreated macaques from SIV challenge at baseline throughout administration of PASylated IFN-1ant (3x weekly or 2x weekly) or placebo saline from weeks 16 to 24 p.i. (a) Heatmap colors represent log2 transformed library size normalized read counts scaled to unit variance across transcript vectors (rows), and normalized to the baseline median sample value of each transcript. Line plots (b) represent the median log2 transformed gene expression estimates for each ISG at week 14 and week 19. Box-whisker plots (c) summarize the differences between weeks 14 and 19 median gene expression estimates for each gene. Error bars indicate lower and upper quartiles. P values were calculated by unpaired t test.